Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03222310 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03222310 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 15 participants.
The verdict
NCT03222310, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will be a single center, open-label, 2-period, fixed-sequence, Phase 1 drug-drug interaction study in healthy subjects. The primary purpose of this study is to evaluate the effect of itraconazole on the PK of ipatasertib and its primary metabolite (G-037720).
Interventions
- DRUG Ipatasertib
- DRUG Itraconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2017-09-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03222310
The ClinicalTrials.gov registry entry for NCT03222310 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipatasertib is the first listed.
NCT03222310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03222310 about?
NCT03222310 is a clinical study titled "A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib". This study will be a single center, open-label, 2-period, fixed-sequence, Phase 1 drug-drug interaction study in healthy subjects. The primary purpose of this study is to evaluate the effect of itraconazole on the PK of ipatasertib and its primary metabolite (G-037720).
What is the current status of trial NCT03222310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-07-18. Estimated completion is 2017-09-06.
What interventions are being tested in trial NCT03222310?
The interventions under investigation include: Ipatasertib (DRUG), Itraconazole (DRUG).
Who is sponsoring clinical trial NCT03222310?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.